HE4, however, has demonstrated potential in identifying high-risk endometrial cancer and may predict response to treatment with levonorgestrel-releasing intrauterine system in low-grade early stage endometrial cancer [45,46]. This evidence concerns the gene WFDC2 and endometrial cancer.